Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption

Advanced Drug Delivery Reviews

Volumn 42, Issue 3, 2000, Pages 175-195

  Ezra, Aviva ^a   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Administration routes; Bisphosphonates; Bone resorption; Delivery systems

Indexed keywords

BONE; CALCIFICATION (BIOCHEMISTRY); DRUG PRODUCTS;

BISPHOSPHONATES; BONE RESORPTION;

CONTROLLED DRUG DELIVERY;

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; ICADRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLENDRONIC ACID;

BIOAVAILABILITY; CALCIFICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; INTESTINE ABSORPTION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE RESORPTION; CHEMISTRY, PHARMACEUTICAL; DIGESTIVE SYSTEM; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; PRODRUGS;

EID: 0034739243     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00061-2     Document Type: Article

References (119)

1. Fleisch H. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann. Med. 29:1997;55-62.
2. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory To the Patient. 1997;Parthenon, Athens.
3. Blomqvist C., Elomaa I. Bisphosphonate therapy in metastatic breast cancer. Acta Oncol. 35:(Suppl. 5):1996;81-83.
4. Body J.J., Coleman R.E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat. Rev. 22:1996;265-287.
5. Delmas P.D., Meunier P.J. The management of Paget′s disease of bone. N. Engl. J. Med. 336:1997;558-566.
6. Kanis J.A. Rationale for the use of bisphosphonates in breast cancer. Acta Oncol. 35:(Suppl. 5):1996;61-67.
7. Laakso M., Jantunen E. Bisphosphonate therapy in multiple myeloma. Acta Oncol. 35:(Suppl. 5):1996;55-56.
8. Licata A.A. Bisphosphonate therapy. Am. J. Med. Sci. 313:1997;17-22.
9. Selby P. Alendronate treatment for osteoporosis: a review of the clinical evidence. Osteoporos. Int. 6:1996;419-426.
10. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora II A.C., Lombardi A., Shan R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333:1995;1437-1443.
11. Bilezikian J.P. Current and future nonhormonal approaches to the treatment of osteoporosis. Int. J. Fertil. 41:1996;148-155.
12. Johansen A., Stone M., Rawlinson F. Bisphosphonates and the treatment of bone disease in the elderly. Drugs Aging. 8:1996;113-126.
13. Rosen C.J., Kessenich C.R. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs. 51:1996;537-551.
14. Fleisch H.A., Russell R.G.G., Bisaz S., Muhlbauer R.C., Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest. 1:1970;12-18.
15. Francis M.D., Russell R.G., Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 165:1969;1264-1266.
16. Francis M.D. The inhibition of calcium hydroxypatite crystal growth by polyphosphonates and polyphosphates. Calcif. Tissue Res. 3:1969;151-162.
17. Meyer J.L., Nancollas G.H. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif. Tissue Res. 13:1973;295-303.
18. Hansen N.M., Felix R., Bisaz S., Fleisch H. Aggregation of hydroxyapatite crystals. Biochim. Biophys. Acta. 451:1976;549-559.
19. Fleisch H., Russell R.G.G., Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 165:1969;1262-1264.
20. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1995;1478-1487.
21. Sahni M., Guenther H.L., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat resorption through the mediation of osteoblasts. J. Clin. Invest. 91:1993;2004-2011.
22. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35:1983;87-99.
23. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 42:1991;919-944.
24. Lin J.H. Bisphosphonates: A review of their pharmacokinetic properties. Bone. 18:1996;75-85.
25. Lin J.H., Chen I., Duggan D.E. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos. 20:(4):1992;473-478.
26. Lin J.H., Duggan D.E., Chen I.W., Ellsworth R.L. Physiological disposition of alendronate, a potent anti-osteolytic biphosphonate, in laboratory animals. Drug Metab. Dispos. 19:1991;926-932.
27. Kasting G.B., Francis M.D. Retention of etidronate in human, dog and rat. J. Bone Miner. Res. 7:1992;513-522.
28. 14C]clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicol. Appl. Pharmocol. 89:1987;287-292.
29. Monkkonen J., Ylitalo P. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration. Eur. J. Drug. Metab. Pharmacokinet. 15:1990;239-243.
30. Wingen F., Schmahl D. Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. Arzneim.-Forsch. 37:1987;1037-1042.
31. Monkkonen J., Koponen H.M., Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol. Toxicol. 66:1990;294-298.
32. Fitton A., McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resortive bone disease. Drugs. 41:1991;289-318.
33. Michael W.R., King W.R., Wakim J.M. Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol. Appl. Pharmacol. 21:1972;503-515.
34. Gertz B., Holland S., Kline W., Matuszewski B., Porras A. Clinical pharmacology of alendronate sodium. Osteoporos. Int. S3:1993;S13-S16.
35. Daley Yates P.T., Dodwell D.J., Pongchaidecha M., Coleman R.E., Howell A. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif. Tissue Int. 49:1991;433-435.
36. Plosker G.L., Goa K.L. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 47:1994;945-982.
37. Recker R.R., Saville P.D. Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution techniQC Toxicol. Appl. Pharmacol. 24:1973;580-589.
38. Hyldstrup L., Flesch G., Hauffe S.A. Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif. Tissue int. 53:1993;297-300.
39. Yakatan G.J., Poynor W.J., Talbert R.L., Floyd B.F., Slough C.L., Ampulski R.S., Benedict J.J. Clodronate kinetics and bioavailability. Clin. Pharmacol. Ther. 31:1982;402-410.
40. Lin J.H., Chen I.-W., Deluna F.A. On the absorption of alendronate in rats. J. Pharm. Sci. 83:1994;1741-1746.
41. Fogelman I., Smith L., Mazess R., Wilson M.A., Bevan J.A. Absorption of oral diphosphonate in normal subjects. Clin. Endocrinol. (Oxf.). 24:1986;57-62.
42. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Freeman A., Quan H., Lasseter K.C., Mucklow J.C., Porras A.G. Studies of the oral biovailability of alendronate. Clin. Pharm. Ther. 58:1995;288-299.
43. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335:1996;1016-1021.
44. Van Hoogdalem E.J., De Boer A.G., Breimer D.D. Intestinal drug absorption enhancement: an overview. Pharmacol. Ther. 44:1989;407-443.
45. Gural R.P., Chung V.S., Shrewsbury R.P., Dittert L.W. Dose-dependent absorption of disodium etidronate. J. Pharm. Pharmacol. 37:1985;443-445.
46. Boulenc X., Marti E., Joyeux H., Roques C., Berger Y., Fabre G. Importance of the paracellullar pathway for the transport of a new bisphosphonate using the human caco-2 monolayers model. Biochem. Pharmacol. 46:1993;1591-1600.
47. Hirtz J. The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br. J. Clin. Pharmacol. 19:(Suppl. 2):1985;77s-83s.
48. Twiss I.M., de Water R., den Hartigh J., Sparidans R., Ramp-Koopmanschap W., Brill H., Wijdeveld M., Vermeij P. Cytotoxic effects of Pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J. Pharm. Sci. 83:1994;699-703.
49. Janner M., Muhlbauer R.C., Fleisch H. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif. Tissue Int. 49:1991;280-283.
50. Grabenstetter R.J., Cilley W.A. Polynuclear complex formation in solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid. I. Complexometric and pH titrations. J. Phys. Chem. 75:1971;676-683.
51. Lamson M.L., Fox J.M., Higuchi W.I. Calcium and 1-hydroxyethylidene-1,1-bisphosphonic acid: Polynuclear complex formation in the physiological range of pH. Int. J. Pharm. 21:1984;143-154.
52. Francis M.D., Martodam R.R. Chemical, biochemical, and medicinal properties of the diphosphonates. Hildebrand R.L. The Role of Phosphonates in Living Systems. 1983;55-96 CRC Press, Boca Raton.
53. Reginster J.Y.L. Oral tiludronate: pharmacological properties and potential usefulness in Paget′s disease of bone and osteoporosis. Bone. 13:1992;351-354.
54. Compston J.E. The therapeutic use of bisphosphonates. Br. Med. J. 309:1994;711-715.
55. Papapoulos S.E. Bisphosphonates pharmacology and use in the treatment of osteoporosis. Osteoporosis. 1996;1209-1234 Academic Press, New York.
56. Mitchell D.Y., Eusebio R.A., Dunlap L.E., Pallone K.A., Nesbitt J.D., Russell D.A., Clay M.E., Bekker P.J. Risedonate gastrointestinal absorption is independent of site and rate of administration. Pharm. Res. 5:1998;228-232.
57. van Hoogdalem E.J., Wackwitz A.T., de Boer A.G., Breimer D.D. 3-Amino-1-hydroxypropylidene-1,1-diphosphonate (APD): a novel enhancer of rectal cefoxitin absorption in rats. J. Pharm. Pharmacol. 41:1989;339-341.
58. Hoffman A., Stepensky D., Ezra A., Breuer E., Golomb G. Mode of administration - dependent pharmacokinetics of bisphosphonates and bioavailability determination. Eur. J. Pharm. Sci. 8:1999;24.
59. Saunders R.L. Jr. Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome. South. Med. J. 70:1977;1327-1329.
60. Dodwell D.J., Howell A., Ford J. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br. J. Cancer. 61:1990;123-125.
61. Harinck H.I., Papapoulos S.E., Blanksma H.J., Moolenaar A.J., Vermeij P., Bijvoet O.L. Paget′s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br. Med. J. Clin. Res. Ed. 295:1987;1301-1305.
62. van Breukelen F.J., Bijvoet O.L., Frijlink W.B., Sleeboom H.P., Mulder H., van Oosterom A.T. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif. Tissue Int. 34:1982;321-327.
63. Marvola M., Rajaniemi M., Marttila E., Vahervuo K., Sothmann A. Effect of dosage form and formulation factors on the adherence of drugs to the esophagus. J. Pharm. Sci. 72:1983;1034-1036.
64. Peter C.P., Handt L.K., Smith S.M. Esophageal irritation due to alendronate sodium tablets. Dig. Dis. Sci. 43:1998;1998-2002.
65. Adami S., Zamberlan N. Adverse Effects of bisphosphonates. Drug Safety. 14:1996;159-170.
66. Blank M.A., Ems B.L., Gibson G.W., Myers W.R., Berman S.K., Phipps R.J., Smith P.N. Nonclinical model for assessing gastric effects of bisphosphonates. Dig. Dis. Sci. 42:1997;281-288.
67. Blank M., Gibson G., Dierckman T., Myers W., Phipps R., Smith P. Gastric damage with nitrogen-containing bisphosphonates (N-BPs) does not correlate with antiresorptive potency. Bone. 22:1998;46S.
68. Twiss I.M., den Hartigh J., Ramp-Koopmanschap W., Vermeij P. The effects of nitrogen-containing bisphosphonates on human epithelial(Caco-2) cells, an in vitro model for intestinal epithelium. J. Bone Miner. Res. 14:1999;784-791.
69. Cohen H., Ivan S.A., Monkkonen J., Seibel M.J., Pinto T., Ezra A., Solomon V., Stepensky D., Sagi H., Ornoy A., Patlas N., Hagele G., Hoffman A., Breuer E., Golomb G. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1) - a novel bisphosphonate. Pharm. Res. 16:1999;1401-1408.
70. Golomb G., Schlossman A., Saadeh H., Levi M., Van Gelder J.M., Breuer E. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo. Pharm. Res. 9:1992;143-148.
71. Reginster J.Y., Jeugmans-Huynen A.M., Albert A., Denis D., Deroisy R., Lecart M.P., Fontaine M.A., Collette J., Franchimont P. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget′s disease of bone. Bone. 9:1988;349-354.
72. Lecart M.P., Reginster J.Y., Deroisy R., Denis D., Sarlet N., Franchimont P. Short-term therapy of Paget′s disease of bone by increasing doses of a new bisphosphonate:4-chloro thiomethylene bisphosphonate. Calcif. Tissue Int. 44:(Suppl. 1):1989;N29.
73. Reginster J.Y., Treves R., Renier J.C., Amor B., Sany J., Ethgen D., Picot C., Franchimont P. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget′s disease of bone. J. Bone Miner. Res. 9:1994;615-619.
74. Reginster J.Y., Colson F., Morlock G., Combe B., Ethgen D., Geusens P. Evaluation of the efficacy and safety of oral tiludronate in Paget′s disease of bone. Arthritis Rheum. 35:1992;967-974.
75. Lufkin E.G., Argueta R., Whitaker M.D., Cameron A.L., Wong V.H., Egan K.S., O′Fallon W.M., Riggs B.L. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos. Int. 4:1994;320-322.
76. Rossini M., Gatti D., Zamberlan N., Braga V., Dorizzi R., Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J. Bone Miner. Res. 9:1994;1833-1837.
77. Adami S., Ortolani S., Broggini M., Carratelli L., Caruso I., Gnessi L., Laurenzi M., Lombardi A., Norbiato G., Pryor-Tillotson S., Reda C., Romanini L., Subrizi D., Wei L., Yates A.J. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 17:1995;383-390.
78. Santora A.C., Bell N.H., Chesnut C.H., Ensrud K., Genant H.K., Grimm R., Harris S.T., McClung M.R., Singer F.R., Stock J.L., Yood R.A., Delmas P.D., Pryor-Tillotson S., Weinberg J. Oral alendronate treatment of bone loss in postmenopausal osteopenic women. J. Bone Miner. Res. 8:1992;S131.
79. Adami S., Baroni M.C., Ortolani S., Broggini M., Carratelli L., Caruso I., Gnessi L., Laurenzi M., Lombardi A., Nobarito J., Ricerca E., Romanini L., Subrizi D., Weinberg J., Yates A.J. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporos. Int. 3:1993;S21-S7.
80. McClung M.R., Yates A.G. Alendronate prevents or reverses bone loss at the spine and hip in recently menopausal women. J. Bone Miner. Res. 8:1993;S141.
81. Seeman E., Nagant de Deuxchaisnes C., Meunier P., Santora A.C. Treatment of postmenopausal osteoporosis with oral alendronate. Bone. 16:1995;120S.
82. Adami S., Mian M., Gatti P., Rossini M., Zamberlan N., Bertoldo F., Cascio V.L. Effects of two oral doses of alendronate in the treatment of Paget′s disease of bone. Bone. 15:1994;415-417.
83. Shrewsbury R.P., Wurster D.E., Dittert L.W. Dose-dependent effect of calcium and magnesium etidronate on salicylic acid absorption in the rat. J. Pharm. Pharmacol. 37:1985;440-442.
84. Vepsalainen J., Vainiotalo P., Nupponen H., Pohjala E. Preparation and identification of tetraamide esters of methylene and (dichloromethylene)bisphosphonates. Acta Chem. Scand. 51:1997;932-937.
85. McKenna C.E., Khawli L., Ahmad W.Y., Pham P., Bongartz J.P. Synthesis of α-halogenated methanediphosphonates. Phosphorus Sulfur. 37:1988;1-12.
86. Ahlmark M.J., Vepsalainen J. Strategies for the selective synthesis of monosubstituted (dicloromethylene)bisphosphonte esters. Tetrahedron. 53:1997;16153-16160.
87. Ahlmark M., Vepsalainen J., Taipale H., Niemi R., Jarvinen T. Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate. J. Med. Chem. 42:1999;1473-1476.
88. Amidon G.L., Merfeld A.E., Dressman J.B. Concentration and pH dependency of alpha-methyldopa absorption in rat intestine. J. Pharm. Pharmacol. 38:1986;363-368.
89. Channer K.S., Virjee J.P. The effect of size and shape of tablets on their esophageal transit. J. Clin. Pharmacol. 26:1986;141-146.
90. Hu M., Borchardt R.T. Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm. Res. 7:1990;1313-1319.
91. Merino M., Peris Ribera J.E., Torres Molina F., Sanchez Pico A., Garcia Carbonell M.C., Casabo V.G., Martin Villodre A., Pla Delfina J.M. Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. Biopharm. Drug Dispos. 10:1989;279-297.
92. Ishizawa T., Tsuji A., Tamai I., Terasaki T., Hosoi K., Fukatsu S. Sodium and pH dependent carrier-mediated transport of antibiotic, fosfomycin, in the rat intestinal brush-border membrane. J. Pharmacobiol. Dyn. 13:1990;292-300.
93. + and pH dependent transport of foscarnet via the phosphate carrier system across intestinal brush-border membrane. Biochem. Pharmacol. 38:1989;1019-1022.
94. Tsuji A., Nakashima E., Kagami I., Yamana T. Intestinal absorption mechanism of amphoteric β-lactam antibiotics II: Michaelis-Menten kinetics of cyclacillin absorption and its pharmacokinetic analysis in rats. J. Pharm. Sci. 70:1981;772-777.
95. Kramer W., Girbig F., Gutjahr U., Kleemann H.W., Leipe I., Urbach H., Wagner A. Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and β-lactam antibiotics. Biochim. Biophys. Acta. 1027:1990;25-30.
96. Swaan P.W., Stehouwer M.F.C., Tukker J.J. Molecular mechanisms for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE inhibitors: enalapril, enalaprilat, and lisinopril. Biochim. Biophys. Acta. 1236:1995;31-38.
97. Friedman D.I., Amidon G.L. Passive and carrier-mediated intestinal absorption components of two angiotensin-converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. 6:1989;1043-1047.
98. Hu M., Subramanian P., Mosberg H.I., Amidon G.L. Use of the peptide carrier system to improve the intestinal absorption of L-α-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa. Pharm. Res. 6:1989;66-70.
99. Ganapathy M.E., Huang W., Wang H., Ganapathy V. Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246:1998;470-475.
100. A. Ezra, A. Hoffman, E. Breuer, I. S. Alferiev, J. Monkkonen, N. El Hanany-Rozen, Gal Weiss, D. Stepensky, I. Gati, H. Cohen, S. Tormalehto, G.L. Amidon, G. Golomb, A peptide prodrug approach for improving bisphosphonate oral absorption, J. Med. Chem., in press.
101. Ezra A., Hoffman A., Breuer E., Weiss G., Golomb G. Carrier-mediated absorption of bisphosphonate prodrug. Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;473-474.
102. Van Gelder J.M., Breuer E., Ornoy A., Schlossman A., Patlas N., Golomb G. Anticalcification and antiresorption effects of bisacylphosphonates. Bone. 16:1995;511-520.
103. Van Gelder J.M., Golomb G. The evaluation of bisphosphonates as potential drugs for the treatment of calcium-related disorders. Ornoy A. Animal Models For Human Related Calcium Metabolic Disorders. 1995;181-205 CRC Press, Boca Raton, FL.
104. Cohen H., Solomon V., Alferiev I.S., Breuer E., Ornoy A., Patlas N., Eidelman N., Hägele G., Golomb G. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm. Res. 15:1998;606-613.
105. Sutton S.C., Engle K., Fix J.A. Intranasal delivery of the bisphosphonate alendronate in the rat and dog. Pharm. Res. 10:1993;924-926.
106. Illum L. Nasal delivery. The use of animal models to predict performance in man. J. Drug Target. 3:1996;427-442.
107. Lauren L., Osterman T., Karhi T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol. Toxicol. 69:1991;365-368.
108. Rossini M., Gatti D., Gerardi D., Zamberlan N., Braga V., Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 24:1999;125-129.
109. Walker P., Watanabe S., Lawlor P., Hanson J., Pereira J., Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann. Oncol. 8:1997;915-916.
110. Patashnik S., Rabinovich L., Golomb G. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J. Drug Target. 4:(6):1997;371-380.
111. Pandey R., Quinn J., Joyner C., Murray D.W., Triffitt J.T., Athanasou N.A. Arthroplasty implant biomaterial particle associated macrophages differentiate into lacunar bone resorbing cells. Ann. Rheum. Dis. 55:1996;388-395.
112. Sabokbar A., Fujikawa Y., Murray D.W., Athanasou N.A. Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. Ann. Rheum. Dis. 57:1998;614-618.
113. Fujisaki J., Tokunaga Y., Takahashi T., Hirose T., Shimojo F., Kagayama A., Hata T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I. synthesis and in vivo characterization of osteotropic carboxyfluorescein. J. Drug Target. 3:1995;273-282.
114. Fujisaki J., Tokunaga Y., Takahashi T., Murata S., Fhimojo F., Hata T. Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery. J. Pharm. Pharmacol. 48:1996;798-800.
115. Fujisaki J., Tokunaga Y., Sawamoto T., Takahashi T., Kimura S., Shimojo F., Hata T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III. Pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J. Drug Target. 4:1996;117-123.
116. Fujisaki J., Tokunaga Y., Takahashi T., Kimura S., Shimojo F., Hata T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV. Effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J. Drug Target. 5:1997;129-138.
117. Christiansen C., Riis B.J. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J. Clin. Endocrinol. Metab. 71:1990;836-841.
118. Lindsay R., Tohme J.F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynecol. 76:1990;290-295.
119. Bai J.P.F., Amidon G.L. Structural specificity of mucosal cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm. Res. 9:1992;969-978.